|3.74||-0.4200||-10.10%||Vol 790.44K||1Y Perf 8.05%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.15 4.01%|
|Target Price||10.25||Analyst Rating||Strong Buy 1.00|
|Potential %||174.06||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★★ — -|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||★★★ — -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||67.43||Earnings Rating||Strong Buy|
|Market Cap||316.69M||Earnings Date||11th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.30|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||633.96K|
|Avg. Monthly Volume||657.68K|
|Avg. Quarterly Volume||778.56K|
CymaBay Therapeutics Inc. (NASDAQ: CBAY) stock closed at 3.74 per share at the end of the most recent trading day (a -10.1% change compared to the prior day closing price) with a volume of 790.44K shares and market capitalization of 316.69M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. CymaBay Therapeutics Inc. CEO is Sujal Shah.
The one-year performance of CymaBay Therapeutics Inc. stock is 8.05%, while year-to-date (YTD) performance is 10.65%. CBAY stock has a five-year performance of -43.07%. Its 52-week range is between 1.6701 and 4.74, which gives CBAY stock a 52-week price range ratio of 67.43%
CymaBay Therapeutics Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 2.67, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -60.79%, a ROC of -59.70% and a ROE of -87.94%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from CymaBay Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.30 for the next earnings report. CymaBay Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for CymaBay Therapeutics Inc. is Strong Buy (1), with a target price of $10.25, which is +174.06% compared to the current price. The earnings rating for CymaBay Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CymaBay Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CymaBay Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.57, ATR14 : 0.27, CCI20 : 70.79, Chaikin Money Flow : 0.17, MACD : 0.30, Money Flow Index : 63.80, ROC : 14.72, RSI : 59.27, STOCH (14,3) : 56.42, STOCH RSI : 0.00, UO : 56.06, Williams %R : -43.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CymaBay Therapeutics Inc. in the last 12-months were: Dennis D. Kim (Buy at a value of $60 800), Sujal Shah (Buy at a value of $100 037)
Mon, 21 Mar 2022 14:35 GMT CymaBay Therapeutics (CBAY) Received its Third Buy in a Row- TipRanks. All rights reserved.
Fri, 18 Mar 2022 10:26 GMT CymaBay Therapeutics (CBAY) Gets a Buy Rating from H.C. Wainwright- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.